The Italian Horizon Scanning Project

Joppi, Roberta; Dematte, L; Menti, Anna Michela; Pase, D.; Poggiani, C.; Mezzalira, Luigi

doi:10.1007/s00228-009-0666-z

Cited by 21 publications

(22 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Initiatives for new drugs include the development of new models to help optimise their use, which centre on three pillars. The three pillars include horizon scanning and budgeting pre-launch, critical drug evaluation peri-launch including possible risk-sharing arrangements, as well as monitoring of prescribing against agreed guidance post launch and, where possible, patient registries to assess the effectiveness and safety of new drugs in routine care [18,19,[58][59][60][61][62][63][64][65]. Considerable effort has been directed towards enhancing the prescribing efficiency of existing drugs, based on generics [1][2][3][4][5][6][7][8][9][10][11]15,33,40,66].…”

Section: Introductionmentioning

confidence: 99%

Essential to increase the use of generics in Europe to maintain comprehensive health care?

Godman

Bennie

Baumgärtel³

et al. 2012

112

View full text Add to dashboard Cite

INTRODUCTION: Reforms have been introduced across Europe to increase prescribing efficiency with existing drugs. These include measures to lower prices of generics as well as increase their prescribing versus originators and patented products in a class or related class. This is essential to maintain comprehensive health care in Europe given continued pressures. The alternative is insufficient funds for new innovative drugs and increasing drug volumes with ageing populations. OBJECTIVE: To review the influence of measures and initiatives to increase the prescribing and dispensing of generics at low prices on ambulatory care prescribing efficiency. In view of this, provide guidance as authorities strive to introduce further reforms to meet their goals. METHODOLOGY: A narrative review of published papers combined with case histories. RESULTS: The different supply- and demand-side measures have reduced generic prices to as low as 2% to 3% of pre-patent loss prices in some cases as well as appreciably enhanced their utilisation. As a result, prescribing efficiency has increased without compromising care. In some cases, the reforms have led to expenditure actually falling despite appreciably increased volumes. CONCLUSIONS: Increasing use of generics at low prices will help maintain the European ideals of comprehensive and equitable health care. However, countries will continually need to learn from each other.

show abstract

Section: Introductionmentioning

confidence: 99%

Essential to increase the use of generics in Europe to maintain comprehensive health care?

Godman

Bennie

Baumgärtel³

et al. 2012

112

View full text Add to dashboard Cite

show abstract

“…Pre-launch activities incorporate horizon scanning and potential budget impact analysis as well as starting to develop potential quality indicators for new medicines. Peri-launch activities include critical drug evaluation, cross-discipline guideline development as well as pricing and reimbursement deliberations (41,43,(129)(130)(131)(132)(133)(134). It is envisaged health authorities will become more critical in their reimbursement deliberations for new medicines given concerns with the limited health gain of most new medicines alongside ever increasing requested prices and their associated budget impact.…”

Section: Proposed Models and Advice To Optimise The Utilisation Of Nementioning

confidence: 99%

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Godman

Malmström

Diogène³

et al. 2014

Expert Review of Clinical Pharmacology

Self Cite

115

132

View full text Add to dashboard Cite

Are new models needed to optimise the utilisation of new medicines to sustain healthcare systems?Godman B 1,2,3 , Malmström RE 4 , Diogene E 5 , Gray A 6 , Jayathissa S 7 , Timoney A 8 , Acurcio FA 9,10 , Alkan A 11 , Brzezinska A 12 , Bucsics A 13 , Campbell S 14,15 AbstractIntroduction: Medicines have made an appreciable contribution to improving health. However, even high income countries are struggling to fund new premium-priced medicines. This will grow necessitating the development of new models to optimise their use. Objective: Review case histories among health authorities to improve the utilisation and expenditure on new medicines. Subsequently, use these to develop exemplar models and outline their implications. Challenges and proposed models: A number of issues and challenges have been identified including the limited innovation level of new medicines alongside increasing requested prices for their reimbursement especially for oncology, orphan diseases, diabetes and HCV. Models centre on the three pillars of pre-, peri, and post-launch including critical drug evaluation and multi-criteria models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure Discussion: Proposed models which involve all key stakeholder groups are critical for the sustainability of healthcare systems or enhancing universal access. The models should help stimulate debate as well as restore trust between key stakeholder groups.

show abstract

“…Com relação aos critérios de filtragem (Inovação e Horizonte de Tempo), observou-se que eles também são utilizados por outros sistemas de MHT 10, 13,14,15 . Isso sugere que os atores têm preferência similar à observada em sistemas de MHT já estabelecidos em outros países.…”

Section: Discussionunclassified

“…No processo de desenvolvimento do MHT para oncológicos da Áustria, esse critério foi redefinido passando a incluir somente a fase III de pesquisa clínica. Em contrapartida, Joppi et al 13 relatam que na agência italiana, Italian Horizon Scanning Project (IHPS) estabelecida em 2006, além da fase III como horizonte de tempo é incluído a fase II para alguns medicamentos oncológicos. Essa abordagem foi utilizada por um período, sendo programada de acordo com os autores uma avaliação futura desse critério para adequar aos objetivos da agência.…”

Section: Discussionunclassified

Mapeamento das preferências de atores estratégicos sobre os critérios de priorização para o monitoramento do horizonte tecnológico em saúde

2016

View full text Add to dashboard Cite

Resumo: Entre as etapas básicas de um sistema de monitoramento do horizonte de tecnologias emergentes, estão a filtragem e a priorização dessas tecnologias. Este trabalho tem por objetivo mapear as preferências dos atores estratégicos do Sistema Único de Saúde (SUS) quanto aos critérios de filtragem e priorização. Foram selecionados dois critérios de filtragem (horizonte de tempo e inovação) e oito critérios de priorização (relevância: epidemiológica, nas políticas de saúde e na prática clínica; impacto: orçamentário no SUS, no custo para o serviço em saúde e na mortalidade; segurança, e aspectos legais, éticos e sociais). A análise de correspondência múltipla foi aplicada para mapear as preferências dos atores nos grupos e entre grupos. Dois grupos foram mais homogêneos entre si e determinantes para a seleção dos critérios de priorização. A influência da formação profissional foi maior que a institucional. A metodologia permitiu a seleção de critérios de forma transparente e a análise das preferências individuais dos participantes.

show abstract

The Italian Horizon Scanning Project

Cited by 21 publications

References 19 publications

Essential to increase the use of generics in Europe to maintain comprehensive health care?

Essential to increase the use of generics in Europe to maintain comprehensive health care?

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Mapeamento das preferências de atores estratégicos sobre os critérios de priorização para o monitoramento do horizonte tecnológico em saúde

Contact Info

Product

Resources

About